Updated:
XIO Group
XIO Group launched in London in 2014 with Joseph Pacini as CEO, flanked by partners Athene Li and Carsten Geyer.
XIO Group
XIO Group launched in London in 2014 with Joseph Pacini as CEO, flanked by partners Athene Li and Carsten Geyer. The firm structured itself as a cross-border specialist, not a generalist buyout shop, targeting mid-market companies in industrials and healthcare across Europe and North America for acquisition and subsequent expansion into China. Its founding thesis depended on a specific macroeconomic assumption: that capital and strategic exits would continue flowing between Western hard-asset businesses and Chinese industrial policy goals. The firm's debut fund raised roughly $1.8 billion by 2016, a significant first close that reflected institutional appetite for the China-access narrative (per Reuters, 2016). XIO deployed this capital into control buyouts, concentrating on companies with proprietary technology or regulatory moats that could be repositioned for the Chinese market. Confirmed acquisitions included the Swiss dental implant maker Straumann's implant subsidiary and a controlling stake in Lumenis, an Israeli medical-laser company, in 2015. The geographic reach spanned the UK, Germany, Israel, and Hong Kong, with additional operations in Shanghai reflecting the strategic corridor the firm attempted to build. XIO scaled quickly, with offices in London, Hong Kong, and Shanghai, and a team drawn from Blackstone, Temasek, and Goldman Sachs. In May 2016, the firm closed its flagship fund at $1.8 billion, making it one of the largest first-time Asia-focused pools raised by an independent manager (per the firm, 2016). The firm maintained a concentrated portfolio approach rather than a fund-of-funds or club-deal model. By 2019, Chinese regulatory restrictions on outbound capital had effectively halted its dealmaking, forcing a pivot whose shape remains only partially visible through scattered public disclosures. XIO occupies an unusual structural niche. It is neither a Western firm dabbling in China nor a state-backed Chinese vehicle, but a founder-led hybrid whose investment committee makes decisions from London with operational execution in Asia. That governance model — Western institutional discipline, Chinese execution — was its differentiator. It also proved its vulnerability. The firm's succession and current deployment trajectory remain opaque, making it a case study in how a well-funded, thesis-driven firm can be structurally disrupted by policy change rather than portfolio performance.
General information
Firm type
Private Equity
Year founded
2014
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Additional offices
Hong Kong · Shanghai
Principals
Joseph Pacini
Chief Executive Officer
Athene Li
Managing Partner
Carsten Geyer
Partner
Sector focus
Frequently asked questions
Who runs investment decisions at XIO Group?
Investment decisions sit with Chief Executive Officer Joseph Pacini and the partnership group, which includes Managing Partner Athene Li and Partner Carsten Geyer. Pacini's background running Blackstone's Asia-Pacific private equity operations makes him the central figure in both origination and committee-level calls. The firm has not publicly detailed a formal investment-committee structure beyond the core partnership.
What happened to XIO Group's cross-border strategy after China's capital controls tightened?
Beginning in 2017, China imposed strict curbs on outbound acquisitions, directly targeting the kind of deals XIO was built to execute — takeovers of Western companies with the aim of relocating capabilities or capturing the China market. The firm's deal flow slowed significantly, and by 2019 it was widely reported to be reassessing its model (public record). XIO has not publicly announced a revised strategy or new fund close since that regulatory shift.
What was XIO Group's flagship fund, and how large was it?
XIO's flagship and only publicly known fund closed at approximately $1.8 billion in 2016 (per Reuters, 2016). It targeted control buyouts in industrials and healthcare, primarily in Europe and North America, with an explicit thesis of China-driven value creation. No subsequent fund has been publicly announced.
Which portfolio companies did XIO Group acquire?
Two high-profile acquisitions defined the portfolio: Lumenis, an Israeli maker of medical lasers, acquired in 2015, and a subsidiary of Switzerland's Straumann Group focused on dental implants. Both fit the firm's pattern of acquiring regulated, technology-heavy healthcare assets with clear China-market applications.
Where does XIO Group's capital come from?
The firm has not publicly disclosed its limited partners. Given Pacini's background and the fund's cross-border thesis, institutional investors in Asia and the Middle East are widely assumed to be significant backers, but no sovereign wealth fund or pension fund has confirmed participation in the public record.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: